Design Therapeutics, Inc.
DSGN
$5.41
$0.214.04%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 6.36% | 56.89% | 10.40% | -10.42% | -1.91% |
| Gross Profit | -6.36% | -56.89% | -10.40% | 10.42% | 1.91% |
| SG&A Expenses | 28.80% | 9.61% | 10.42% | -21.47% | -18.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.38% | 41.79% | 10.40% | -13.69% | -33.43% |
| Operating Income | -43.38% | -41.79% | -10.40% | 13.69% | 33.43% |
| Income Before Tax | -61.82% | -59.52% | -15.28% | 17.42% | 40.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.82% | -59.52% | -15.28% | 17.42% | 40.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.82% | -59.52% | -15.28% | 17.42% | 40.85% |
| EBIT | -43.38% | -41.79% | -10.40% | 13.69% | 33.43% |
| EBITDA | -43.82% | -42.10% | -10.43% | 13.87% | 33.70% |
| EPS Basic | -60.96% | -58.75% | -14.07% | 18.33% | 41.48% |
| Normalized Basic EPS | -61.01% | -58.75% | -14.02% | 18.38% | 41.49% |
| EPS Diluted | -60.96% | -58.75% | -14.07% | 18.33% | 41.48% |
| Normalized Diluted EPS | -61.01% | -58.75% | -14.02% | 18.38% | 41.49% |
| Average Basic Shares Outstanding | 0.54% | 0.48% | 1.05% | 1.13% | 1.08% |
| Average Diluted Shares Outstanding | 0.54% | 0.48% | 1.05% | 1.13% | 1.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |